Sage Therapeutics Q2 EPS $(2.68) Misses $(2.55) Estimate, Sales $2.47M Miss $2.94M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics reported Q2 losses of $2.68 per share, missing the analyst consensus estimate of $2.55 by 5.1%. This is a 25.82% decrease from the same period last year. The company also reported quarterly sales of $2.47 million, missing the analyst consensus estimate of $2.94 million by 15.85%. However, this is a 64.82% increase from the same period last year.
August 07, 2023 | 10:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics' Q2 earnings and sales missed estimates, which could negatively impact the stock price in the short term.
Sage Therapeutics' Q2 earnings and sales missed analyst estimates, which is typically seen as a negative signal by the market and could lead to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100